Molecular Templates (Molecular Templates) Interest Expense

: $-2.65 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Molecular Templates's interest expense for the three months ended in Dec. 2023 was $ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.65 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Molecular Templates's Operating Income for the three months ended in Dec. 2023 was $ -5.37 Mil. Molecular Templates's Interest Expense for the three months ended in Dec. 2023 was $ -0.04 Mil. Molecular Templates did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Molecular Templates Interest Expense Historical Data

The historical data trend for Molecular Templates's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Templates Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-1.30

-1.71

-3.37

-4.72

-2.65

Molecular Templates Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.35	-1.40	-1.19	-0.03	-0.04

Molecular Templates Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.65 Mil.

Molecular Templates (NAS:MTEM) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Molecular Templates's Interest Expense for the three months ended in Dec. 2023 was $-0.04 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-5.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $9.74 Mil.

Molecular Templates's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Molecular Templates did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Molecular Templates (Molecular Templates) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Templates Inc (NAS:MTEM) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

9301 Amberglen Boulevard, Suite 100, Austin, TX, USA, 78729

Website

https://www.mtem.com

Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer.

Executives

Maurizio Voi	officer: Chief Medical Officer	4 MAGUIRE ROAD, LEXINGTON MA 02421
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Sean Mclennan	officer: CFO & Treasurer	C/O MOLECULAR TEMPLATES, INC., 93010 AMBERGLEN BLVD., SUITE 100, AUSTIN TX 78729
Kevin M. Lalande	director, 10 percent owner	201 WEST 5TH STREET, AUSTIN TX 78701
Shv Management Services, Llc	10 percent owner	FROST TOWER, 401 CONGRESS AVENUE, SUITE 2950, AUSTIN TX 78701
Gabriela Gruia	director	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Jason S. Kim	officer: See Remarks	9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
Patrick G Enright	10 percent owner	CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Bakker Juliet Tammenoms	10 percent owner	LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
David Hirsch	director, 10 percent owner	C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Longitude Venture Partners Iii, L.p.	10 percent owner	800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Scott D Morenstein	director	C/O CAXTON ALTERNATIVE MANAGEMENT LP, 1330 SIXTH AVENUE, 20TH FLOOR, NEW YORK NY 10019